Fat Grafting Technique for Fecal Incontinence

NCT ID: NCT03882632

Last Updated: 2020-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-11

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fecal Incontinence affects an estimated 2-20% of the general population, and up to 50% of the elderly and institutionalized population. Patients with incontinence tend to suffer in silence; they often do not seek help because of embarrassment and stigma. They often become confined to their homes because they are afraid of having an "accident". Although this is not a life-threatening condition, the psychological, emotional, and social impact can be devastating.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate reconstructive lipoplasty with micro-fragmented autologous adipose tissue (Lipogems®) in female patients with fecal incontinence. Our hypothesis is that placing approximately up to 90 cc of Lipogems® will yield an effective increase in surviving material (over normal fat injection) due to the refinement of the process and result in decreased fecal incontinence over the long term.

Human Adipose Tissue (Fat) possesses regenerative properties in its stromal vascular fraction (SVF). SVF contains nests of pericytes and human MSC mesenchymal stem cells). MSCs are multipotent cells (also called stromal multipotent cells), that possess the ability to differentiate into various tissues, such as bone, tendon, articular cartilage, ligaments, muscle, and fat. Upon fragmentation of adipose tissue using Lipogems®, viable elements are preserved with pericyte identity within an intact stromal vascular niche. It is hypothesized that upon trauma or disruption of this adipose tissue, the regenerative cells within the intact perivascular niche interact via micro vesicles with the microenvironment at the transplant site to promote angiogenesis, neuronal sprouting and fibroblast production thereby stimulating increased vasculature (circulation, nerve regeneration, muscle growth and tone in the urethral sphincter and in the urethral muscles). If these changes are observed, long lasting regenerative changes occur and should be long lasting versus the shorter live effects of the bulking effect by undisrupted fat tissue.

This is a pilot study of 10 subjects will be treated with local injections of Lipogems® and followed for up to two years. Subjects will receive a full history and examination by a single colorectal surgeon. A clear history of their incontinence frequency, Wexner Incontinence Score, Fecal Incontinence Quality of Life Scale, surgical history, and childbirth history will be collected for all registered patients in order to categorize the study participant according to incontinence-type.

All patients will undergo anal physiology testing and endoanal ultrasound. Pre and post measurements will be recorded and compared for objective evaluation. Patients will be evaluated subjectively with the Wexner incontinence Score and Fecal Incontinence Quality of Life Scale.

Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally. This will be done in the procedure room or operating room with IV sedation and local anesthesia. This will all occur in the same setting on the same day.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Fecal Incontinence

Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally

Group Type EXPERIMENTAL

Fat Grafting for Fecal Incontinence

Intervention Type DEVICE

Autologous adiopse tissue harvesting/grafting using Lipogems

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fat Grafting for Fecal Incontinence

Autologous adiopse tissue harvesting/grafting using Lipogems

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fat Grafting

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: \>18 \< 65 years
2. Sex: females
3. Affected by fecal incontinence (moderate to severe) independently from the etiology and previous treatments
4. No restrictions to follow-up for 24 months after treatment
5. Willing and able to provide informed consent

Exclusion Criteria

1. Present diagnosis of cancer (not in remission)
2. Patients with uncorrected rectal prolapse
3. Overflow incontinence
4. Patients with neurogenic bowel or spinal cord injuries
5. Any patients unable to give informed consent, including members of vulnerable populations
6. Patients with concomitant pelvic floor disorders, like paradoxical puborectalis contraction or pelvic floor dysfunction
7. Chronic diarrhea
8. Patients with chronic steroid use
9. Patients 17 and under
10. Anal Sepsis (abscess and/or fistula)
11. Inability to undergo the intended diagnostic tests and follow-up
12. Pregnancy
13. Diagnosis of Diabetes Mellitus 1 and 2
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lifespan

OTHER

Sponsor Role collaborator

Melanie Salerno, RN

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Melanie Salerno, RN

Dr. Leslie Roth

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lifespan

Providence, Rhode Island, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Melanie Salerno

Role: CONTACT

4014447148

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Melanie Salerno, RN

Role: primary

401-444-7148

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1125611

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biofeedback for Fecal Incontinence
NCT00124904 COMPLETED NA